Abstract:Background Invasive fungal infection (IFI) is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of pathogens determination and illness of the hosts. The aim of this study was to evaluate the efficacy and safety of itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematologic malignancies.Methods Two hundred and seventy-four patients with hematologic malignancies who had suspected fungal infections were enrolled in 18 centers across China between April 2008 and April 2009. Empirical antifungal therapy with intravenous itraconazole 200 mg twice daily was given for the first two days, followed by 200 mg once daily for the next 12 days. Oral itraconazole solution was sequential for follow-up therapy if necessary. Five composite end points were evaluated for the response, which was more restrictive and adopted for the first time in such study in China.Results The intent-to-treat analysis included data from 274 patients (full analysis set, FAS), of whom 248 were included as the per-protocol population (PPS). As the composite end point of five indices was concerned, the overall response rate was 43.4%. Seperately, defervescence was achieved in 90% of patients in which 55.5% occured during neutropenia. The mean time to defervescence was 2.71 days. Absence of breakthrough IFI during drug administration or within the first 7 days after study completion was observed in 71.5% of patients. Fifty-five point five percent patients with IFI at baseline was successfully treated. Ninety point five percent patients survived for at least 7 days after completing the study. PPS analysis revealed that the duration of neutropenia >= 10 days was a statistically significant negative predictor for the response. The withdrawal rate due to drug-related toxicity or lack of efficacy was 11.0%. The incidence of adverse events was 22.6%, in which 11.6% was study drug related. The most frequent adverse events were mild to moderate liver toxicity.Conclusion ltraconazole shows desirable efficacy and safety as empirical antifungal therapy for febrile neutropenic patients with hematologic malignancies. Chin Med J 2011;124(22):3670-3675

Effectiveness analysis of fluconazole prophylaxis of fungus infection in patients with hematological diseases

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients A retrospective observational study

Efficacy and Safety of Itraconazole on Invasive Fungal Infections in 66 Patients with Malignant Hematological Diseases

[Clinical Study of Amphotericin B in the Treatment of Invasive Fungal Infection in 111 Hematological Disorder Patients with Neutrocytopenia].

Does High-Dose Cytarabine Cause More Fungal Infection in Patients with Acute Myeloid Leukemia Undergoing Consolidation Therapy

Posaconazole Vs. Fluconazole As Invasive Fungal Infection Prophylaxis in China: A Multicenter, Randomized, Open-Label Study

[Efficacy and Safety of Intravenous Itraconazole in Different Antifungal Strategies for Patients Undergoing Intensive Chemotherapy or Hematopoietic Stem Cell Transplantation].

Low‐dose fluconazole as a useful and safe prophylactic option in patients receiving allogeneic hematopoietic stem cell transplantation

Efficacy and Safety of Micafungin as Prophylaxis for Invasive Fungal Disease in Neutropenic Patients with Hematologic Malignancies

Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China.

The Efficacy and Safety of Voriconazole As Antifungal Prophylaxis of Invasive Fungal Infection for Hematology Patients

Meta-analysis of Therapeutic Efficacy of Itraconazole Against Invasive Fungal Infection in Hematology Patients

Fluconazole is as effective as other anti-mold agents in preventing early invasive fungal disease after allogeneic stem cell transplantation: assessment of antifungal therapy in haematological disease in China.

Clinical analysis of micafungin in prevention of fungal infection in neutropenic stage in patients with allogeneic hematopoietic stem cell transplantation

Clinical analysis on the effect of itraconazole oral solution versus fluconazole in the prevention of fungal infection in neutropenic patients with acute leukemia

A Systematic Review on Fluconazole and Itraconazole As Antifungal Prophylaxis of Invasive Fungal Infection after Transplantation

Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase Iv Trial

Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials

Treatment of cryptococcal meningitis with low-dose amphotericin B and flucytosine.

Recombinant Human Granulocyte Colony-stimulating Factor in Treatment of Malignant Hematological Diseases with Fungus Infection and Its Clinical Significance